Latest News and Press Releases

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical...

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical...

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol NTHI), a clinical-stage medical...

WESTLAKE VILLAGE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has been recognized by Pharma Tech Outlook as the Top...

NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain and central...

NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...

FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1...

New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...

LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from...

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, is proud to be presenting at the 2024 California Investment Forum (CIF),...